Accord Healthcare Receives Positive CHMP Opinion for Denosumab, Osvyrti®, and Jubereq®
Osvyrti ®– Bone / Osteoporosis (60mg Pre-Filled Syringe) Jubereq ®– Oncology (120mg Vial) Joe Dunford, Accord's Vice ...
Targeted Oncology15h
FDA Oncology Actions: March 2025 Approvals and Designations
On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell ...
Bayer expects its latest menopause relief drug to be out soon
Menopause-related health problems, both physical and mental, have become a pressing issue for women at the transformative age ...
Le Lézard19h
Immunovia publishes the Annual Report for 2024
Immunovia AB (publ) today announced that the Annual Report for 2024 has been published. The annual report can be downloaded in pdf format and is available on Immunovia's website. For more information, ...
Le Lézard19h
Breaking Barriers: VARP, Inc. and MAT on Empowered with Meg Ryan
Discover how VARP, Inc. is transforming lives by bridging the gap between traditional and modern addiction treatment, highlighting the power of Medication-Assisted Treatment (MAT) and ...
PMLive15h
Organon/Henlius announce EMA validation for Perjeta biosimilar HLX11
Organon and Shanghai Henlius Biotech have announced that the European Medicines Agency (EMA) has validated a marketing authorisation application for HLX11, a biosimilar candidate referencing Roche’s ...